SLC5A2 and angina pectoris: Our data demonstrated a substantial decrease in HRR following empagliflozin, indicating that SGLT2 inhibitors may have antisympatholytic effects that might relieve angina symptoms by lowering resting HR and cardiac demand.56, 57